Biogen Idec Bolsters MS, Oncology Pipeline Via PDL Co-Development Pact
This article was originally published in Pharmaceutical Approvals Monthly
Biogen Idec will leverage its multiple sclerosis and oncology franchises to co-develop Protein Design Labs’ daclizumab and volociximab for MS and cancer applications under a deal worth up to $800 mil.
You may also be interested in...
Tysabri withdrawal effects: GlaxoSmithKline, Antisense Therapeutics halt MS drug Phase II trials, citing identical mechanism of action. Teva, Serono, Schering jockey for advantage over Biogen Idec following additional reports of PML in Tysabri recipients, addition of Avonex liver warning
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class